Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · see citing works

The Molecular Signatures Database Hallmark Gene Set Collection

Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · see citing works

Adjusting batch effects in microarray expression data using empirical Bayes methods

Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658 · see citing works

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,838 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

Comprehensive molecular characterization of clear cell renal cell carcinoma

The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · see citing works

A pathology atlas of the human cancer transcriptome

Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371 · see citing works

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

Circular binary segmentation for the analysis of array-based DNA copy number data

Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,256 · see citing works

GenePattern 2.0

Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,035 · see citing works

Absolute quantification of somatic DNA alterations in human cancer

Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,003 · see citing works

Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs

Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,589 · see citing works

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy

Kadoch, C., Hargreaves, D. C., Hodges, H. C., Elias, L., Ho, L., Ranish, J. A., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,443 · see citing works

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1523 · Cited by 1,433 · see citing works

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,278 · see citing works

Integrated molecular analysis of clear-cell renal cell carcinoma

Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,223 · see citing works

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Gerlinger, M., Horswell, S. D., Larkin, J., Rowan, A., Salm, M., Varela, I., Fisher, R. A., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,211 · see citing works

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Brastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A. N., Jones, R. T., Allen, E. M. V., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0369 · Cited by 1,084 · see citing works

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Allen, E. M. V., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E. N., Luna, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1092-z · Cited by 949 · see citing works

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J. R., Zhang, T., Adleff, V., Phallen, J. A., Wali, N., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 898 · see citing works

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · see citing works

A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries

Fisher, S., Barry, A. J., Abreu, J., Minie, B., Nolan, J., Delorey, T. M., Young, G., Fennell, T. J., Allen, A., Ambrogio, L., et al. (2011) · Genome biology · doi:10.1186/gb-2011-12-1-r1 · Cited by 683 · see citing works

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

Allen, E. M. V., Wagle, N., Stojanov, P., Perrin, D., Cibulskis, K., Marlow, S., Jané‐Valbuena, J., Friedrich, D. C., Kryukov, G. V., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 533 · see citing works

Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation

Costello, M., Pugh, T. J., Fennell, T. J., Stewart, C., Lichtenstein, L., Meldrim, J. C., Fostel, J., Friedrich, D. C., Perrin, D., Dionne, D. A., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1443 · Cited by 523 · see citing works

Comprehensive identification of mutational cancer driver genes across 12 tumor types

Tamborero, D., González-Pérez, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C., Reimand, J., Lawrence, M. S., Getz, G. A., Bader, G. D., Li, J., et al. (2013) · Scientific Reports · doi:10.1038/srep02650 · Cited by 475 · see citing works

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

Kapur, P., Peña‐Llopis, S., Christie, A. L., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 466 · see citing works

Paired exome analysis of Barrett's esophagus and adenocarcinoma

Stachler, M. D., Taylor-Weiner, A. N., Peng, S., McKenna, A., Agoston, A. T., Odze, R. D., Davison, J. M., Nason, K. S., Loda, M. F., Leshchiner, I., et al. (2015) · Nature Genetics · doi:10.1038/ng.3343 · Cited by 366 · see citing works

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network

Hakimi, A. A., Ostrovnaya, I., Reva, B. A., Schultz, N. D., Chen, Y., Gönen, M., Liu, H., Takeda, S., Voss, M. H., Tickoo, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3886 · Cited by 358 · see citing works

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

Beuselinck, B., Job, S., Becht, É., Karadimou, A., Verkarre, V., Couchy, G., Giraldo, N. A., Rioux-Leclercq, N. C., Molinié, V., Sibony, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1128 · Cited by 315 · see citing works

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2839 · Cited by 295 · see citing works

ContEst: estimating cross-contamination of human samples in next-generation sequencing data

Cibulskis, K., McKenna, A., Fennell, T. J., Banks, E., DePristo, M. A., & Getz, G. A. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr446 · Cited by 290 · see citing works

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma

Nargund, A. M., Pham, C. G., Dong, Y., Wang, P. I., Osmangeyoglu, H. U., Xie, Y., Aras, Ö., Han, S., Oyama, T., Takeda, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.074 · Cited by 215 · see citing works

Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma

Kwiatkowski, D., Choueiri, T., Fay, A., Rini, B., Thorner, A., de Velasco, G., Tyburczy, M., Hamieh, L., Albigès, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 207 · see citing works

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

Hsieh, J. J.-D., Chen, D., Wang, P. I., Marker, M., Redzematovic, A., Chen, Y., Selçuklu, S. D., Weinhold, N., Bouvier, N., Huberman, K. H., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.10.007 · Cited by 204 · see citing works

Loss of PBRM1 expression is associated with renal cell carcinoma progression

Pawłowski, R., Mühl, S. M., Sulser, T., Krek, W., Moch, H., & Schraml, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27822 · Cited by 170 · see citing works

Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL −/− clear cell renal carcinoma

Gao, W., Li, W., Xiao, T., Liu, X. S., & Kaelin, W. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619726114 · Cited by 151 · see citing works

Integrated genomic analyses of ovarian carcinoma

The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works

Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity

Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 120 · see citing works

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups

de Velasco, G., Miao, D., Voss, M. H., Hakimi, A. A., Hsieh, J. J.-D., Tannir, N. M., Tamboli, P., Appleman, L. J., Rathmell, W. K., Allen, E. M. V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0110 · Cited by 74 · see citing works

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

Carlo, M. I., Manley, B. J., Patil, S., Woo, K. M., Coskey, D. T., Redzematovic, A., Arcila, M. E., Ladanyi, M., Lee, W., Chen, Y., et al. (2017) · Kidney Cancer · doi:10.3233/kca-160003 · Cited by 49 · see citing works

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Fay, A. P., de Velasco, G., Ho, T. H., Allen, E. M. V., Murray, B. A., Albiges, L. K., Signoretti, S., Hakimi, A. A., Stanton, M., Joaquim Bellmunt, B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0086 · Cited by 41 · see citing works

Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma

Nam, S. J., Lee, C., Park, J. H., & Moon, K. C. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.01.010 · Cited by 38 · see citing works

The growth rate of “clinically significant” renal cancer

Gofrit, O. N., Yutkin, V., Zorn, K. C., Duvdevani, M., Landau, E. H., Hidas, G., & Pode, D. (2015) · SpringerPlus · doi:10.1186/s40064-015-1385-9 · Cited by 8 · see citing works

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

TISIDB: an integrated repository portal for tumor–immune system interactions

Ru, B., Wong, C. N., Tong, Y., Zhong, J. Y., Zhong, S. S. W., Wu, W. C., Chu, K. C., Wong, C. Y., Lau, C. Y., Chen, I., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz210 · Cited by 2,388 · see citing works

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works

Therapeutic cancer vaccines

Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581 · see citing works

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302 · see citing works

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192 · see citing works

Therapeutic cancer vaccines

Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works

Translational Applications of Hydrogels

Correa, S., Grosskopf, A. K., Hernandez, H. L., Chan, D. C., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,153 · see citing works

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992 · see citing works

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · see citing works

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · see citing works

Intratumoral heterogeneity in cancer progression and response to immunotherapy

Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 823 · see citing works

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 802 · see citing works

Review of precision cancer medicine: Evolution of the treatment paradigm

Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 776 · see citing works

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741 · see citing works

Brain immunology and immunotherapy in brain tumours

Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 733 · see citing works

The SWI/SNF complex in cancer — biology, biomarkers and therapy

Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 705 · see citing works

Cancer immunotherapy: Pros, cons and beyond

Tan, S., Li, D., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 694 · see citing works

Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K. A., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 659 · see citing works

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 648 · see citing works

Clear cell renal cell carcinoma ontogeny and mechanisms of lethality

Jonasch, E. W., Walker, C. L., & Rathmell, W. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00359-2 · Cited by 647 · see citing works

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.015 · Cited by 613 · see citing works

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620 · see citing works

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562 · see citing works

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Braun, D. A., Street, K., Burke, K. P., Cookmeyer, D. L., Denize, T., Pedersen, C. B., Gohil, S. H., Schindler, N. R., Pomerance, L., Hirsch, L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.013 · Cited by 502 · see citing works

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 469 · see citing works

Genomic correlates of response to immune checkpoint blockade

Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works

Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma

Vuong, L. H., Kotecha, R. R., Voss, M. H., & Hakimi, A. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0499 · Cited by 437 · see citing works

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

Krishna, C., DiNatale, R. G., Kuo, F., Srivastava, R. M., Vuong, L. H., Chowell, D., Gupta, S., Vanderbilt, C., Purohit, T. A., Liu, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.007 · Cited by 427 · see citing works

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma

Atkins, M. B., & Tannir, N. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.009 · Cited by 393 · see citing works

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 384 · see citing works

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Hu, J., Yu, A., Othmane, B., Qiu, D., Li, H., Li, C., Liu, P., Ren, W., Chen, M., Gong, G., et al. (2021) · Theranostics · doi:10.7150/thno.53649 · Cited by 387 · see citing works

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Chan, L.-C., Li, C.-W., Xia, W., Hsu, J.-M., Lee, H.-H., Cha, J.-H., Wang, H.-L., Yang, W.-H., Yen, E.-Y., Chang, W.-C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126022 · Cited by 332 · see citing works

UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma

Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jiménez-Sánchez, A., Trabish, S., Lee, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.032 · Cited by 370 · see citing works

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03520-4 · Cited by 370 · see citing works

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics

Borcherding, N. C., Vishwakarma, A., Voigt, A. P., Bellizzi, A. M., Kaplan, J., Nepple, K. G., Salem, A. K., Jenkins, R. W., Zakharia, Y., & Zhang, W. (2021) · Communications Biology · doi:10.1038/s42003-020-01625-6 · Cited by 359 · see citing works

The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy

Lindeboom, R. G. H., Vermeulen, M., Lehner, B., & Supek, F. (2019) · Nature Genetics · doi:10.1038/s41588-019-0517-5 · Cited by 327 · see citing works

Pan-cancer deconvolution of tumour composition using DNA methylation

Chakravarthy, A., Furness, A., Joshi, K., Ghorani, E., Ford, K., Ward, M. J., King, E. V., Lechner, M., Marafioti, T., Quezada, S. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05570-1 · Cited by 327 · see citing works

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356 · see citing works

Mechanisms of Cancer Resistance to Immunotherapy

Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 357 · see citing works

Cancer Epigenetics, Tumor Immunity, and Immunotherapy

Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 298 · see citing works

Implementing TMB measurement in clinical practice: considerations on assay requirements

Büttner, R., Longshore, J. W., López‐Ríos, F., Merkelbach‐Bruse, S., Normanno, N., Rouleau, É., & Penault-Llorca, F. M. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 342 · see citing works

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Pérez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324 · see citing works

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 316 · see citing works

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H. A., Egger, J. V., Concepcion, C. P., Paul, S., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1825 · Cited by 298 · see citing works

Targeting the DNA damage response in immuno-oncology: developments and opportunities

Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J., Pasero, P., & Postel-Vinay, S. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 300 · see citing works

Deep learning-based prediction of the T cell receptor–antigen binding specificity

Lu, T., Zhang, Z., Zhu, J., Wang, Y., Jiang, P., Xiao, X., Bernatchez, C., Heymach, J. V., Gibbons, D. L., Wang, J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00383-2 · Cited by 295 · see citing works

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers

Parkhurst, M. R., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Jia, L., Ivey, G. D., Li, Y. F., El‐Gamil, M., Lalani, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1494 · Cited by 290 · see citing works

Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α

Wu, L., Jin, Y., Zhao, X., Tang, K., Zhao, Y., Tong, L., Yu, X., Xiong, K., Luo, C., Zhu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.001 · Cited by 292 · see citing works

Prognostic factors and prognostic models for renal cell carcinoma: a literature review

Klatte, T., Rossi, S. H., & Stewart, G. D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2309-4 · Cited by 274 · see citing works

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth

Roumenina, L. T., Daugan, M. V., Noé, R., Petitprez, F., Vano, Y. A., Sánchez-Salas, R., Becht, É., Meilleroux, J., Clec'h, B. L., Giraldo, N. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0891 · Cited by 273 · see citing works

The current state of molecular testing in the treatment of patients with solid tumors, 2019

El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264 · see citing works

Checkpoint inhibitor immunotherapy in kidney cancer

Xu, W. V., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 259 · see citing works

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Au, L., Hatipoglu, E., de Massy, M. R., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R. H., Byrne, F., Horswell, S. D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 258 · see citing works

The Human Protein Atlas—Spatial localization of the human proteome in health and disease

Digre, A., & Lindskog, C. (2020) · Protein Science · doi:10.1002/pro.3987 · Cited by 247 · see citing works

Sex-associated molecular differences for cancer immunotherapy

Ye, Y., Jing, Y., Liang, L., Mills, G. B., Diao, L., Liu, H., & Han, L. (2020) · Nature Communications · doi:10.1038/s41467-020-15679-x · Cited by 242 · see citing works

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240 · see citing works

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma

Braun, D. A., Ishii, Y., Walsh, A. M., Allen, E. M. V., Wu, C. J., Shukla, S. A., & Choueiri, T. K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3158 · Cited by 236 · see citing works

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

Lalani, A. A., McGregor, B. A., Albiges, L. K., Choueiri, T. K., Motzer, R. J., Powles, T. B., Wood, C. G., & Bex, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.010 · Cited by 232 · see citing works

Towards individualized therapy for metastatic renal cell carcinoma

Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0209-1 · Cited by 231 · see citing works

Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer

Chen, H., Yao, J., Bao, R., Dong, Y., Zhang, T., Du, Y., Wang, G., Ni, D., Xun, Z., Niu, X., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01322-w · Cited by 234 · see citing works

Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy

Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 229 · see citing works

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathiéu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud‐Rotureau, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 224 · see citing works

Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians

Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 210 · see citing works

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion

Fu, Q., Xu, L., Wang, Y., Jiang, Q., Liu, Z., Zhang, J., Zhou, Q., Zeng, H., Tong, S., Wang, T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.030 · Cited by 211 · see citing works

Kidney cancer: The next decade

Turajlic, S., Swanton, C., & Boshoff, C. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181617 · Cited by 209 · see citing works

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target

Wang, X., Tokheim, C. J., Gu, S. S., Wang, B., Tang, Q., Li, Y., Traugh, N. C., Zeng, Z., Zhang, Y., Li, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.006 · Cited by 204 · see citing works

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors

Kovacs, S., Fekete, J. T., & Győrffy, B. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01079-6 · Cited by 202 · see citing works

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies

Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento‐Ribeiro, A. B., García‐Aranda, M., & Rivas, J. D. L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 200 · see citing works

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 197 · see citing works

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 194 · see citing works

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

Wang, J., Ge, J., Wang, Y., Xiong, F., Guo, J., Jiang, X., Zhang, L., Deng, X., Gong, Z., Zhang, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28479-2 · Cited by 195 · see citing works

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

Li, J., Wang, W., Zhang, Y., Cieslik, M. P., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 192 · see citing works

Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancerPreprint

Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 192 · see citing works

BAP1: Not just a BRCA1-associated protein

Louie, B. H., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102091 · Cited by 191 · see citing works

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression

Hu, J., Wang, S., Hou, Y., Chen, Z., Liu, L., Li, R., Li, N., Zhou, L., Yang, Y., Wang, L., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01662-5 · Cited by 194 · see citing works

Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

Segovia, C., José‐Eneriz, E. S., Munera-Maravilla, E., Martínez‐Fernández, M., Gárate, L., Miranda, E., Vilas‐Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 188 · see citing works

Chromosome 3p Loss–Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma

Hsieh, J. J.-D., Le, V. H., Oyama, T., Ricketts, C. J., Ho, T. H., & Cheng, E. H. Y. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2549 · Cited by 185 · see citing works

Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer

Ju, M., Bi, J., Wei, Q., Jiang, L., Guan, Q., Zhang, M., Song, X., Chen, T., Fan, J., Li, X., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa345 · Cited by 183 · see citing works

Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine

Xue, C., Chu, Q., Zheng, Q., Jiang, S., Bao, Z., Su, Y., Lü, J., & Li, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01003-0 · Cited by 186 · see citing works

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Okamura, R., Kato, S., Lee, S., Jimenez, R. E., Sicklick, J. K., & Kurzrock, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000438 · Cited by 184 · see citing works

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Wang, Z., Wu, L., Li, B., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., Fan, Y., Yu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00727 · Cited by 182 · see citing works

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181 · see citing works

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

Liu, X.-D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A. G., Zhang, X., Lam, T., Pilie, P. G., Zhu, H., Beckermann, K. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15959-6 · Cited by 177 · see citing works

Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer

Zhou, M., Zhang, Z., Bao, S., Hou, P. K., Yan, C., Su, J., & Sun, J. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa047 · Cited by 178 · see citing works

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 173 · see citing works

Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

Tischkowitz, M. D., Huang, S., Banerjee, S. N., Hague, J., Hendricks, W. P. D., Huntsman, D. D., Lang, J. D., Orlando, K. A., Oza, A. M., Pautier, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3797 · Cited by 170 · see citing works

Genomic profiling in renal cell carcinoma

Dizman, N., Philip, E. J., & Pal, S. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0301-x · Cited by 170 · see citing works

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

Bilen, M. A., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Shabto, J. M., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2018) · Cancer · doi:10.1002/cncr.31778 · Cited by 167 · see citing works

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165 · see citing works

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

Newell, F., da Silva, I. P., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164 · see citing works

Patient-derived Ovarian Cancer Organoids Capture the Genomic Profiles of Primary Tumours Applicable for Drug Sensitivity and Resistance Testing

Nanki, Y., Chiyoda, T., Hirasawa, A., Ookubo, A., Itoh, M., Ueno, M., Akahane, T., Kameyama, K., Yamagami, W., Kataoka, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69488-9 · Cited by 165 · see citing works

Genetic and metabolic hallmarks of clear cell renal cell carcinoma

Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 160 · see citing works

Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors

Leruste, A., Tosello, J., Ramos, R. N., Tauziède‐Espariat, A., Brohard, S., Han, Z., Beccaria, K., Andrianteranagna, M. J. D. D., Caudana, P., Nikolić, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 160 · see citing works

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group

Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 159 · see citing works

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 154 · see citing works

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation

Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C. T., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 156 · see citing works

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · see citing works

Highlights from Recent Cancer Literature

(2018) · Cancer Research · doi:10.1158/0008-5472.1373.78.6

PBRM1 loss promotes tumour response to immunotherapy

Otto, G. P. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.7 · Cited by 5 · see citing works

Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.

Miao, D., Margolis, C. A., Martini, D. J., Mullane, S. A., Cullen, D., Horak, C. E., Wind‐Rotolo, M., Hellmann, M. D., Voss, M. H., Motzer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3016 · Cited by 4 · see citing works

Abstract B48: PBRM1 loss promotes resistance to immunotherapy in RCC

Liu, X., Kong, W., Hoang, A. G., Zhang, X., Zhou, L., Pilie, P. G., Isgandrova, S., Moczygemba, M. M., & Jonasch, E. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm18-b48